Complement system and age-related macular degeneration: drugs and challenges

Age-related macular degeneration (AMD) is directly attributable to vision loss, posing significant pressure on public health. AMD is recognized to be a multi-factorial disease and among them, complement system is under heated discussion in recent years. In this review, we start with an overview of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jiali, Sun, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650090/
https://www.ncbi.nlm.nih.gov/pubmed/31409975
http://dx.doi.org/10.2147/DDDT.S206355
_version_ 1783438096194338816
author Wu, Jiali
Sun, Xiaodong
author_facet Wu, Jiali
Sun, Xiaodong
author_sort Wu, Jiali
collection PubMed
description Age-related macular degeneration (AMD) is directly attributable to vision loss, posing significant pressure on public health. AMD is recognized to be a multi-factorial disease and among them, complement system is under heated discussion in recent years. In this review, we start with an overview of complement pathways involved in AMD and their therapies correspondingly. Finally, we discuss the development of the therapeutics existed now. Also, we enclose a list of drugs undergoing clinical trials.
format Online
Article
Text
id pubmed-6650090
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66500902019-08-13 Complement system and age-related macular degeneration: drugs and challenges Wu, Jiali Sun, Xiaodong Drug Des Devel Ther Review Age-related macular degeneration (AMD) is directly attributable to vision loss, posing significant pressure on public health. AMD is recognized to be a multi-factorial disease and among them, complement system is under heated discussion in recent years. In this review, we start with an overview of complement pathways involved in AMD and their therapies correspondingly. Finally, we discuss the development of the therapeutics existed now. Also, we enclose a list of drugs undergoing clinical trials. Dove 2019-07-19 /pmc/articles/PMC6650090/ /pubmed/31409975 http://dx.doi.org/10.2147/DDDT.S206355 Text en © 2019 Wu and Sun. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Wu, Jiali
Sun, Xiaodong
Complement system and age-related macular degeneration: drugs and challenges
title Complement system and age-related macular degeneration: drugs and challenges
title_full Complement system and age-related macular degeneration: drugs and challenges
title_fullStr Complement system and age-related macular degeneration: drugs and challenges
title_full_unstemmed Complement system and age-related macular degeneration: drugs and challenges
title_short Complement system and age-related macular degeneration: drugs and challenges
title_sort complement system and age-related macular degeneration: drugs and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650090/
https://www.ncbi.nlm.nih.gov/pubmed/31409975
http://dx.doi.org/10.2147/DDDT.S206355
work_keys_str_mv AT wujiali complementsystemandagerelatedmaculardegenerationdrugsandchallenges
AT sunxiaodong complementsystemandagerelatedmaculardegenerationdrugsandchallenges

Ejemplares similares